Pulmatrix Receivables 2014-2024 | PULM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Pulmatrix receivables from 2014 to 2024. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Pulmatrix receivables from 2014 to 2024. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$160.1B
Vertex Pharmaceuticals (VRTX)	$123.9B
Gilead Sciences (GILD)	$122.2B
Bristol Myers Squibb (BMY)	$116.5B
CSL (CSLLY)	$82.8B
Regeneron Pharmaceuticals (REGN)	$79.3B
GSK (GSK)	$75.4B
Argenex SE (ARGX)	$40B
Alnylam Pharmaceuticals (ALNY)	$35.9B
BioNTech SE (BNTX)	$28.8B
BeiGene (ONC)	$22.4B
Biogen (BIIB)	$20.7B
Illumina (ILMN)	$19.5B
Insmed (INSM)	$14.5B
Incyte (INCY)	$14.4B
Intra-Cellular Therapies (ITCI)	$13.5B
Moderna (MRNA)	$12.9B
Genmab (GMAB)	$12.8B
Genmab (GNMSF)	$12.7B
BioMarin Pharmaceutical (BMRN)	$12.3B
Bio-Techne Corp (TECH)	$11.9B
Vaxcyte (PCVX)	$11.1B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
Sarepta Therapeutics (SRPT)	$10.7B
Exact Sciences (EXAS)	$10B
Bio-Rad Laboratories (BIO.B)	$9.6B
Exelixis (EXEL)	$9.6B
QIAGEN (QGEN)	$9.4B
Repligen (RGEN)	$9.1B
Roivant Sciences (ROIV)	$7.9B